Knoll Capital Management is an investment fund managing more than $96.3 billion ran by Fred Knoll. There are currently 37 companies in Mr. Knoll’s portfolio. The largest investments include Aldeyra Therapeutics Inc and Applied Therapeutics, together worth $33.1 billion.
As of 7th November 2023, Knoll Capital Management’s top holding is 3,031,915 shares of Aldeyra Therapeutics Inc currently worth over $20.3 billion and making up 21.0% of the portfolio value.
Relative to the number of outstanding shares of Aldeyra Therapeutics Inc, Knoll Capital Management owns less than approximately 0.1% of the company.
In addition, the fund holds 5,162,088 shares of Applied Therapeutics worth $12.9 billion, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Biohaven Pharmactl Hldg Co L worth $12.8 billion and the next is Avadel Pharmaceuticals plc worth $6.18 billion, with 600,000 shares owned.
Currently, Knoll Capital Management's portfolio is worth at least $96.3 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Knoll Capital Management office and employees reside in Miami, Florida. According to the last 13-F report filed with the SEC, Fred Knoll serves as the President at Knoll Capital Management.
In the most recent 13F filing, Knoll Capital Management revealed that it had opened a new position in
Kinross Gold and bought 440,000 shares worth $2.01 billion.
This means they effectively own approximately 0.1% of the company.
Kinross Gold makes up
12.2%
of the fund's Materials sector allocation and has grown its share price by 22.0% in the past year.
The investment fund also strengthened its position in Aldeyra Therapeutics Inc by buying
16,247 additional shares.
This makes their stake in Aldeyra Therapeutics Inc total 3,031,915 shares worth $20.3 billion.
Aldeyra Therapeutics Inc dropped 56.4% in the past year.
On the other hand, there are companies that Knoll Capital Management is getting rid of from its portfolio.
Knoll Capital Management closed its position in Altimmune Inc on 14th November 2023.
It sold the previously owned 173,864 shares for $614 million.
Fred Knoll also disclosed a decreased stake in Ocular Therapeutix Inc by 1.0%.
This leaves the value of the investment at $1.26 million and 400 shares.
The two most similar investment funds to Knoll Capital Management are Wfa Of San Diego and Paragon Financial Partners, Inc. They manage $96.4 billion and $96.3 billion respectively.
Knoll Capital Management’s portfolio is diversified across 6 sectors.
Currently, their heaviest sector is Health Care — making up 48.0% of
the total portfolio value.
The fund focuses on investments in the United States as
32.4% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
19% of the total holdings value.
On the other hand, small-cap stocks make up 13.5% of the portfolio.
The average market cap of the portfolio companies is close to $38.9 billion.
These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Aldeyra Therapeutics Inc |
0.54%
3,031,915
|
$20,253,192,000 | 21.02% |
| Applied Therapeutics, Inc. |
49.63%
5,162,088
|
$12,853,599,000 | 13.34% |
| Biohaven Pharmactl Hldg Co L |
8.88%
490,422
|
$12,755,876,000 | 13.24% |
| Avadel Pharmaceuticals plc |
20.00%
600,000
|
$6,180,000,000 | 6.41% |
| Hookipa Pharma Inc |
No change
5,517,385
|
$3,398,709,000 | 3.53% |
| Verona Pharma |
No change
200,000
|
$3,260,000,000 | 3.38% |
| Seabridge Gold, Inc. |
208.25%
246,597
|
$2,601,598,000 | 2.70% |
| Vaneck Gold Miners Etf |
No change
91,850
|
$2,471,683,000 | 2.57% |
| Global X Silver Miners Etf 37954y848 |
No change
89,700
|
$2,143,830,000 | 2.23% |
| Kinross Gold Corp. |
Opened
440,000
|
$2,006,400,000 | 2.08% |
| Franco Nev Corp Cad |
107.14%
14,500
|
$1,935,605,000 | 2.01% |
| Wheaton Precious Metals Corp |
Opened
47,500
|
$1,926,125,000 | 2.00% |
| Agnico Eagle Mines Ltd |
Opened
40,000
|
$1,818,000,000 | 1.89% |
| Silvercrest Metals Inc Cad |
141.18%
410,000
|
$1,808,100,000 | 1.88% |
| Entera Bio Ltd |
No change
2,484,275
|
$1,801,099,000 | 1.87% |
| Equinox Gold Corp |
Opened
420,929
|
$1,780,529,000 | 1.85% |
| Vaneck Junior Gold Miners Etf |
No change
53,150
|
$1,713,024,000 | 1.78% |
| MAG Silver Corp. |
Opened
160,000
|
$1,659,200,000 | 1.72% |
| Booz Allen Hamilton Hldg Cor |
No change
13,000
|
$1,420,510,000 | 1.47% |
| First Majestic Silver Corporation |
Opened
275,000
|
$1,410,750,000 | 1.46% |
| Visa Inc |
No change
4,850
|
$1,115,548,000 | 1.16% |
| Thermo Fischer Scientific Inc |
No change
2,100
|
$1,062,957,000 | 1.10% |
| CVS Health Corp |
No change
14,500
|
$1,012,390,000 | 1.05% |
| Altria Group Inc. |
No change
22,700
|
$954,535,000 | 0.99% |
| Northrop Grumman Corp. |
No change
2,165
|
$953,011,000 | 0.99% |
| Alamos Gold Inc. |
Opened
80,000
|
$903,200,000 | 0.94% |
| Lockheed Martin Corp. |
Opened
2,150
|
$879,264,000 | 0.91% |
| Royal Gold, Inc. |
Opened
7,550
|
$802,791,000 | 0.83% |
| Pan American Silver Corp |
Opened
54,085
|
$783,150,000 | 0.81% |
| Osisko Gold Royalties Ltd |
No change
400,000
|
$732,000,000 | 0.76% |
| Altimmune Inc |
Closed
173,864
|
$613,739,000 | |
| Amylyx |
Opened
24,772
|
$453,575,000 | 0.47% |
| Orgenesis Inc |
No change
634,738
|
$393,537,000 | 0.41% |
| Omega Therapeutics Inc. |
No change
173,010
|
$371,971,000 | 0.39% |
| Ocuphire Pharma, Inc. |
No change
100,000
|
$335,000,000 | 0.35% |
| New Pac Metals Corp |
Opened
131,654
|
$233,027,000 | 0.24% |
| Bioxcell |
100.00%
60,000
|
$151,800,000 | 0.16% |
| Ocular Therapeutix Inc |
99.80%
400
|
$1,256,000 | 0.00% |
| No transactions found | |||
| Showing first 500 out of 38 holdings | |||